These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
28 related articles for article (PubMed ID: 3894723)
1. [Demonstration of antinuclear factors using indirect immunofluorescence in scleroderma patients]. Nebe H; Blume N Dermatol Monatsschr; 1971 Jan; 157(1):27-31. PubMed ID: 4938251 [No Abstract] [Full Text] [Related]
2. [Anticentromere antibodies and other antinuclear antibodies in progressive systemic sclerosis]. Rojas C; Silva MC; Pérez L; Ruiz F Rev Med Chil; 1985 May; 113(5):409-14. PubMed ID: 3912881 [No Abstract] [Full Text] [Related]
3. [Importance of certain laboratory indicators for determination of the activity of systemic scleroderma]. Shiapak EA; Drampian FS; Kessel' VP; Aznaurian AV; Lobanova IN Zh Eksp Klin Med; 1973; 13(3):96-100. PubMed ID: 4599068 [No Abstract] [Full Text] [Related]
4. [Antinuclear antibodies in mesenchymal scleroderma and progressive systemic sclerosis (author's transl)]. Sugiura M; Hashimoto T; Kurihara S; Nishikawa T; Hatano H Nihon Hifuka Gakkai Zasshi; 1980 Sep; 90(10):935-7. PubMed ID: 7012401 [No Abstract] [Full Text] [Related]
5. [Determination of antinuclear autoantibodies in progressive systemic sclerosis and its clinical significance]. Jiang M; Wang HZ; Yuan X Zhonghua Nei Ke Za Zhi; 1988 Feb; 27(2):112-4, 136. PubMed ID: 3053068 [No Abstract] [Full Text] [Related]
6. [Antinuclear antibodies and clinical signs in systemic scleroderma--relationship to score diagnosis]. Takehara K; Ishibashi Y; Moroi Y Nihon Hifuka Gakkai Zasshi; 1985 Feb; 95(2):135-40. PubMed ID: 3894723 [No Abstract] [Full Text] [Related]